A biotech company is developing a new treatment that could potentially slow down the ageing process. This therapy makes use of so-called “telomere rivers”, which are fragments of telomeres that play an important role in protecting our chromosomes. Telomeres can be seen as the protective caps at the end of our DNA strands, which become increasingly shorter as we age.
Previous research in mice showed that these telomere fragments could significantly extend lifespan. Although this result is promising, there were doubts due to the small number of test mice and the difference between animal testing and humans. Therefore, a phase 1 clinical trial is now being started for the first time to test the safety and efficacy of the therapy in humans.
Phase 1 studies are the first step in human research and focus primarily on determining whether a new treatment is well tolerated. This research is important to be able to better understand afterwards whether the drug is also effective in slowing down the ageing process in humans. The aim is to restore the immune system and reduce age-related problems.
This development fits into a broader current within science that is searching for ways to make healthy ageing possible. Targeting telomeres is one of the promising directions in this regard. Although it is still early days, this new therapy offers hope for more healthy years in our life expectancy.
For anyone interested in longevity and healthy ageing, it is important news that such innovative methods are now also being investigated in humans.
Source: Reason
